niftify.in

CNBC TV18

Zydus Lifesciences to acquire Sterling Biotech's API business for ₹84 crore

In August this year when Zydus acquired a 50% stake in Sterling Biotech Ltd (SBL), the company negotiated for the right to acquire the 'Target Business' of SBL at a pre-defined value.

Business Standard

Zydus Lifesciences to acquire Sterling Biotech's API biz for Rs 84 crore

Zydus Lifesciences Ltd on Tuesday said it will acquire the 'Target Business' of Sterling Biotech primarily engaged in manufacturing of fermentation-based active pharmaceutical ingredients products and a production facility at Masa in Gujarat for a pre-agreed sum of Rs 84 crore. In August this year when Zydus acquired a 50 per cent stake in Sterling Biotech Ltd (SBL), the company negotiated for the right to acquire the 'Target Business' of SBL at a pre-defined value. "This right has been exercised by the company," Zydus Lifesciences said in a regulatory filing. The board of directors of the company at their meeting held on September 17, 2024, have approved a business transfer agreement (BTA) to purchase the active pharmaceutical ingredients (API) business -- the Target Business -- of SBL, on a going concern basis, on slump sale basis, without values being assigned to individual assets and liabilities, on cash-free and debt-free basis at a pre-defined lump-sum consideration of Rs 84 .

Business Standard

Stocks To Watch: Patanjali Foods, Zydus Life, Max Health, Tata Power, MTNL

The US FDA has issued a warning letter to Zydus Lifesciences citing significant manufacturing lapses at its Gujarat-based plant.

Business Line

USFDA cites manufacturing lapses at Zydus Lifesciences' Jarod plant

USFDA sought a detailed remediation plan from the drug firm with timelines to address the findings of the contamination hazards risk assessment.

Business Standard

USFDA cites manufacturing lapses at Zydus Lifesciences' Gujarat plant

The US health regulator has pulled up Zydus Lifesciences for manufacturing lapses at its Gujarat-based plant. In a warning letter to company's Managing Director Sharvil Patel, the US Food and Drug Administration (USFDA) noted that the drug maker failed to investigate contamination identified in drug products at its Jarod-based plant in Vadodara district. The USFDA said it inspected the manufacturing facility from April 15 to 23, 2024. "This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals," it added. It further said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated." A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. Elaborating on the manufacturing issues at the facility, USFDA noted: "Your firm failed to thorough

CNBC TV18

Zydus Life arm signs exclusive US licensing and supply pact for MRI contrast agents

Zydus' agreement with Viwit Pharmaceuticals covers the supply of gadobutrol and gadoterate meglumine injections, widely used in MRI procedures to enhance the visibility of internal organs, blood vessels, and tissues. Shares of Zydus Lifesciences Ltd ended at ₹1,118.50, down by ₹1.65, or 0.15%, on the BSE.

CNBC TV18

Zydus Lifesciences completes phase IIa trial of Usnoflast in ALS patients

undefined

CNBC TV18

GIC Re, GSK Pharma, Godfrey Phillips, IEX and more: Top stocks to watch out for on September 4

stocks to watch, GIC Re, GSK Pharma, Godfrey Phillips, IEX, Zydus Lifesciences, KIMS, AU Small Finance Bank, PDS, ZEEL, Hitachi Energy, NHPC, Mankind Pharma and more, these are the stocks to watch for today.

CNBC TV18

Zydus Lifesciences says FDA warning letter to injectable unit will not affect supply to US

The letter, received on August 30, 2024, identifies concerns related to current good manufacturing practices (cGMP), which are already under remediation by the company. Shares of Zydus Lifesciences Ltd ended at ₹1,113.50, up by ₹2, or 0.18%, on the BSE.

Business Standard

UBS Group AG sells shares of 7 companies worth Rs 4,961 crore

Swiss financial services company UBS Group AG on Friday sold shares of seven companies, including Oil India and Dixon Technologies (India), for Rs 4,961 crore via open market transactions. Zurich-based UBS Group AG through its affiliate UBS Principal Capital Asia offloaded shares of seven companies through separate bulk deals on the National Stock Exchange (NSE). According to the bulk deal data available on the NSE, UBS Principal Capital Asia offlloaded shares of Oil India worth Rs 972 crore, sold shares of Dixon Technologies India for Rs 904 crore, disposed of shares of Rail Vikas Nigam Ltd for Rs 797 crore. UBS Principal Capital Asia also sold shares of Zydus Lifesciences for Rs 756 crore, disposed of scrips of Vodafone Idea, Oracle Financial Services Software and Prestige Estates Projects for a combined value of Rs 1,531 crore on the NSE. Meanwhile, Copthall Mauritius Investment offloaded 20.92 lakh shares of Prestige Estate for Rs 378 crore. UBS Principal Capital Asia picked u

The Economic Times

UBS Group AG sells shares of 7 Indian companies worth Rs 4,961 crore

UBS Group AG sold shares of seven companies, including Oil India and Dixon Technologies, for Rs 4,961 crore through open market transactions. The sales were made via its affiliate, UBS Principal Capital Asia, and included stakes in Rail Vikas Nigam, Zydus Lifesciences, Vodafone Idea, Oracle Financial Services Software, and Prestige Estates Projects.

The Economic Times

Zydus Lifesciences gets warning letter from USFDA for its Jarod injectable unit

Zydus Lifesciences received a warning letter from the USFDA regarding its injectables manufacturing facility at Jarod, following an inspection in April 2024. The letter cites violations of cGMP regulations. Zydus must respond within 15 days and take remedial action. The warning limits new product launches, impacting business growth in the US market.

Business Standard

Zydus Lifesciences gets USFDA nod to mkt Scopolamine transdermal system

Zydus Lifesciences Ltd on Friday said it has received the final approval from the US Health regulator to market its Scopolamine transdermal system indicated to prevent nausea and vomiting under different circumstances. The approval granted by the US Food and Drug Administration (USFDA) is to market the Scopolamine transdermal system of dosage 1 mg/3 days, Zydus Lifesciences said in a regulatory filing. The Scopolamine transdermal system will be produced at the group's transdermal manufacturing site at SEZ, Matoda, Ahmedabad, it added. Scopolamine transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness. "This is the fifth abbreviated new drug application (ANDA) approval for Zydus in the transdermal portfolio, leveraging the group's strengths in the manufacturing of complex drug device dosage forms," the company said. Scopolamine Transdermal System

The Economic Times

Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system

Zydus Lifesciences Ltd has received USFDA approval to market its Scopolamine transdermal system, which helps prevent nausea and vomiting under various conditions, including after surgery and due to motion sickness. The product, with a dosage of 1 mg/3 days, will be manufactured in Ahmedabad.

The Economic Times

Zydus Lifesciences gets USFDA nod for generic medication

Zydus Lifesciences has received approval from the USFDA to market Amantadine extended-release capsules (68.5 mg) and tentative approval for Gocovri (137 mg) capsules for treating Parkinson's disease. The drug will be produced at the company's Ahmedabad facility, making Zydus eligible for 180 days of exclusivity for Amantadine capsules.

CNBC TV18

Zydus Lifesciences secures USFDA approval for Amantadine extended-release capsules

Shares of Zydus Lifesciences Ltd ended at ₹1,113.85, up by ₹5.40, or 0.49% on the BSE.

CNBC TV18

LTIMindtree, ICICI Prudential, Airtel, Asian Energy Services and more: Top stocks to watch out for on August 28

Stocks to watch, LTIMindtree, ICICI Prudential, Airtel, Asian Energy Services, Jio Financial Services, Zydus Lifesciences, Awfis Space Solutions, UPL, Carysil and more, these are the stocks to watch for today.

Business Line

Zydus Lifesciences acquires 50% stake in Sterling Biotech for fermentation-based protein business; shares drop nearly 6%

The joint venture aims to establish a “state-of-the-art” facility for manufacturing fermented animal-free protein for global markets.

The Economic Times

Zydus Lifesciences shares fall 6%, brokerages neutral on Sterling Biotech deal

Zydus Lifesciences Share Price: Zydus Lifesciences' shares fell 6% to Rs 1,109 after acquiring a 50% stake in Sterling Biotech for Rs 550 crore. Analysts maintain neutral ratings with target prices of Rs 1,020 and Rs 1,210.

Business Line

Stocks that will see action today: August 26, 2024

Buzzing stocks: Trent, BEL, BHEL, Divi’s Lab, LTIMindtree, JSW Energy, Dr Reddy’s Lab, Zydus Lifesciences, Zen Tech, Ashoka Buildcon, Alembic Pharma, Nibe, Tranindia Real, Uno Minda, Debock Industries

Business Standard

Zydus Lifesciences to acquire 50% stake in Sterling Biotech

Firm will focus on animal-free protein production

Business Standard

Zydus Life arm inks pact to acquire 50% stake in Sterling Biotech

Zydus LIfesciences said that its wholly owned subsidiary, Zydus Animal Health and Investments has entered into share purchase and share subscription agreement (SPSSA) with Perfect Day to acquire 50% stake in Sterling biotech.

Business Standard

Zydus acquires 50% stake in Sterling Biotech

Zydus Lifesciences through its wholly owned subsidiary, and Perfect Day Inc., a Temasek portfolio company (Perfect Day) have signed an agreement wherein Perfect Day will sell its ~50% shareholding in Sterling Biotech (SBL). Post this transaction, Sterling Biotech will become a 50:50 Joint Venture (JV) with equal representation on the Board.

Business Line

MSCI resumes Adani stock adjustments after Hindenburg report

MSCI announced inclusion of eight other stocks such as Bosch, Dixon Technologies India, Oil India, PB Fintech, Phoenix Mills, RVNL, Vodafone Idea, and Zydus Lifesciences.

Business Standard

Zydus Lifesciences Q1 FY25 results: PAT up 31%, revenue rises 21%

The API business contributed 2 per cent to consolidated revenues, growing 2 per cent Y-o-Y to Rs 141.5 crore

Business Standard

Zydus Lifesciences Q1FY25 results: Net profit rises 31% to Rs 1,420 cr

Zydus Lifesciences on Friday said its consolidated net profit increased 31 per cent year on year to Rs 1,420 crore in the first quarter ended June 2024 on the back of robust sales. The drug maker had reported a net profit of Rs 1,087 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 6,207 crore in the period under review as compared to Rs 5,140 crore in the June quarter of FY24, Zydus Lifesciences said in a statement. "Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q1 performance," Zydus Lifesciences Managing Director Sharvil Patel said. Execution success of company's differentiated pipeline in the US and outperformance of India geography business were particularly noteworthy, he added. "We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future," Patel said. The company said its India sales

The Economic Times

Zydus barred from selling cancer biosimilar, for now

The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta (pertuzumab), due to a patent infringement lawsuit filed by Roche. The court granted an interim injunction against Zydus after Roche argued that Sigrima and another biosimilar, Womab from Dr Reddy's, violate its patents. Zydus had received conditional approval for its pertuzumab biosimilar but launched it amidst ongoing litigation, prompting the court to intervene to prevent potential market disruption.

Business Standard

Zydus Life gets USFDA approval to market heart failure treatment drug

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in adults. The approval by the US Food and Drug Administration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing. Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company added.

The Economic Times

Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drug

Zydus Lifesciences Ltd has received final approval from the USFDA to market its generic Sacubitril and Valsartan tablets for treating chronic heart failure in adults. The tablets come in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. The drug will be manufactured in Ahmedabad.

Business Standard

Zydus and Dr Reddy's ink licensing agreement to co-market Pertuzumab in India

Zydus Lifesciences and Dr. Reddy's Laboratories announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India.

Business Line

F&O Query: Should you sell Zydus Lifesciences call option?

Only a decisive break of the base at ₹1,000 can turn the trend bearish